Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
NYU Sells Part of its Remicade Royalty
May 14, 2007
| A version of this story appeared in
Volume 85, Issue 20
New York University has sold a portion of its royalty interest in the arthritis drug Remicade to Royalty Pharma, a New York City-based firm that buys revenue-producing intellectual property. NYU will receive $650 million in cash plus additional payments should Remicade, marketed by Johnson & Johnson, exceed certain sales milestones. NYU retains the portion of the royalty payable to the university researchers who developed the monoclonal antibody. Royalty Pharma also has royalty interests in drugs such as Abbott Laboratories' Humira, Amgen's Neupogen, and Genentech's Rituxan.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter